toplogo
Sign In

Growth Hormone Impact on T2D Control in Adolescents


Core Concepts
Proteins related to growth hormone activity can serve as risk markers for type 2 diabetes in adolescents.
Abstract

The content discusses the significant links between plasma levels of proteins involved in growth hormone activity and the controllability of type 2 diabetes in adolescents. Key points include:

  • Dr. Chang Lu's research on growth hormone mediators and their association with glycemic failure in youth with type 2 diabetes.
  • Potential applications of these findings in predicting type 2 diabetes onset and identifying at-risk adolescents for more intervention.
  • The impact of growth hormone changes during puberty on the aggressive course of type 2 diabetes.
  • Analysis of growth hormone-related peptides in adolescents with type 2 diabetes and their correlation with glycemic failure.
  • Suggestions for future studies to explore the relationship between growth hormone signaling and glycemic control in children and adolescents with prediabetes and obesity.
edit_icon

Customize Summary

edit_icon

Rewrite with AI

edit_icon

Generate Citations

translate_icon

Translate Source

visual_icon

Generate MindMap

visit_icon

Visit Source

Stats
"Plasma levels of three proteins involved in growth hormone activity showed significant links to the controllability of type 2 diabetes in adolescents." "The primary outcome showed a 39%-52% incidence of failure during 5 years of follow-up depending on the specific treatments the study participants received." "An increase in insulin-like growth factor-1 significantly linked with a reduced incidence of glycemic failure and improved glycemia and beta-cell function." "Increasing plasma levels of growth hormone receptor significantly linked with an increased rate of glycemic failure, hyperglycemia, insulin resistance, and diminished beta-cell function." "An increase in insulin-like growth factor binding protein-1 significantly linked with glycemic failure and hyperglycemia at 36 months, and with higher insulin sensitivity at baseline."
Quotes
"Plasma growth hormone mediators are associated with glycemic failure in youth with type 2 diabetes." "Puberty-associated changes in growth hormone and related peptides could be why type 2 diabetes starts during puberty." "The increase in growth hormone during puberty can unmask a physiologic and genetic predisposition to developing type 2 diabetes."

Key Insights Distilled From

by Mitchel L. Z... at www.medscape.com 08-09-2023

https://www.medscape.com/viewarticle/995304
Growth Hormone Links With Worse T2D Control in Adolescents

Deeper Inquiries

How can the findings of this research impact the early detection and prevention of type 2 diabetes in adolescents?

The findings of this research can have a significant impact on the early detection and prevention of type 2 diabetes in adolescents by identifying potential biomarkers that could serve as risk markers for incident type 2 diabetes. By measuring plasma levels of proteins involved in growth hormone activity, healthcare providers may be able to predict the onset of type 2 diabetes in adolescents. This predictive capability could help in targeting high-risk individuals for more aggressive preventive care, potentially leading to early interventions that could slow or prevent the progression to type 2 diabetes.

What are the potential implications of growth hormone signaling on glycemic control in children with prediabetes and obesity?

The potential implications of growth hormone signaling on glycemic control in children with prediabetes and obesity are significant. Changes in levels of growth hormone-associated peptides during puberty could explain why children with type 2 diabetes have a more aggressive course of the disorder. High levels of growth hormone during puberty may cause insulin resistance, which, in combination with poor beta-cell function, could lead to the development of type 2 diabetes. Understanding the role of growth hormone signaling in glycemic control could help in identifying children at risk for aggressive disease and targeting them for interventions to prevent the onset of type 2 diabetes.

How might the use of insulin treatment or GLP-1 agonists benefit adolescents identified as high risk for type 2 diabetes?

For adolescents identified as high risk for type 2 diabetes, the use of insulin treatment or GLP-1 agonists could offer potential benefits in managing the condition. Early initiation of insulin treatment could help preserve beta-cell function, which is crucial in maintaining glycemic control. Additionally, treatment with GLP-1 agonists, which interact with insulin-like growth factor-1 receptors on beta cells, may also be beneficial in improving glycemic control in high-risk adolescents. These interventions could potentially slow or prevent the progression to type 2 diabetes in individuals identified as high risk, offering them better management and outcomes in the long term.
0
star